[1] Khan N, et al. Impact of Anti-TNFand Thiopurine Medications on the Development of COVID-19 in Patients With IBD: A Nationwide Veterans Administration Cohort Study. Gastroenterology 2020;159(4):1545-1546.e1.

[2] Attauabi M, et al. Prevalence and Outcomes of COVID-19 Among Patients With IBD—A Danish Prospective Population-based Cohort Study. J Crohns Colitis 2021;15(4):540-50.

[3] Lelong M, et al. P207: COVID-19:a prevalence rate two times lower than that of the general population in French patients with IBD treated with intravenous biologicagents. Congrès ECCO 2022.

[4] Harris RJ, et al. Life in lockdown:experiences of patientswith IBD during COVID-19. BMJ Open Gastroenterol. 2020;7(1):e000541.

[5] Singh S, et al. Risk of Severe Coronavirus Disease 2019 in Patients With IBD in the US: A Multicenter Research Network Study. Gastroenterology 2020;159(4):1575-78.e4.

[6] Vuitton L, et al. P140 : Immunomodulators are protective againstsevere COVID 19: results from a large multicentre cohort of IBD patients. Congrès ECCO 2022.

[7] Brenner EJ, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With IBD: Results From an International Registry. Gastroenterology 2020;159(2):481-491.e3.

[8] Hadi Y, et al. Incidence, outcomes, and impact of COVID-19 on IBD: propensity matched research network analysis. Aliment Pharmacol Ther. 2022;55(2):191-200.

[9] Velayos FS, et al. Prior Immunosuppressive Therapy and Severe Illness Among Patients Diagnosed with SARS-CoV-2: a Community-Based Study. J Gen Intern Med. 2021;36(12):3794-801.

[10] Amiot A, et al. Impact de l'épidémie de Covid-19 sur la prise en charge des patients atteints de MICI : étude prospective ancillaire nichée dans la cohorte européenne prospective I-CARE. JFHOD 2022, C134.

[11] Sultan S, et al. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology 2020 Jul;159(1):320-334.e27.

[12] Ng SC, et al. COVID-19 and the gastrointestinal tract: more than meets the eye.Gut. 2020;69(6):973-4.

[13] Sharma E, et al. The effects of COVID-19 on IBD prescribing and service provision in a UK tertiarycentre. GastroHep. 2020;2(6):318-26.

[14] Chen J, et al. Impact of Medication Discontinuation on PatientsWith IBD During the COVID-19 Outbreak. Gastroenterology 2021;160(6):2223.

[15] Magro F, et al. IBD Management During the COVID-19 Outbreak: The Ten Do’s and Don’ts from the ECCO-COVID Taskforce. J Crohns Colitis 2020;14(Supplement_3):S798-806.

[16] Recommandations du GETAID sur COVID-19 et vaccination chez les patients MICI. Mise à jour en février 2022. www.getaid.org.

[17] Walldorf J, et al. SARS-CoV-2 Vaccination in Patients With IBD—Fear and Desire. IBD. 2021;izab150.

[18] Botwin GJ, et al. Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With IBD. Am J Gastroenterol. 2021 [cité 23 févr 2022]; Publish Ahead of Print. Disponible sur: https://journals.lww.com/10.14309/ ajg.0000000000001342.

[19] Hadi YB, et al. COVID-19 Vaccination Is Safe and Effective in Patients With IBD: Analysis of a LargeMulti-institutional Research Networkin the United States. Gastroenterology 2021;161(4):1336-1339.e3.

[20] Alexander JL, et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patientswith IBD (VIP):a multicentre, prospective, case- control study. Lancet Gastroenterol Hepatol. 2022; Disponible sur: https://www.sciencedirect.com/science/article/pii/S246812532200005X.